0VS Stock Chart & Stats
€4.88
-€0.04(-0.81%)
At close: 4:00 PM EDT
€4.88
-€0.04(-0.81%)
Day’s Range― - ―
52-Week Range€4.25 - €17.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)8.00
Market Cap
€887.41M
Enterprise Value€738.28
Total Cash (Recent Filing)€490.60M
Total Debt (Recent Filing)€43.59M
Price to Earnings (P/E)―
Beta2.30
Next Earnings
Nov 05, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding197,048,170
10 Day Avg. Volume0
30 Day Avg. Volume8
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)5.45
Price to Sales (P/S)67.10
P/FCF Ratio-15.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€15.20Price Target Upside211.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.96
Revenue Forecast (FY)€43.14M
Bulls Say, Bears Say
Bulls Say
Cash Runway / LiquidityA near‑term multi‑year cash runway materially reduces immediate financing pressure and gives management time to advance lead programs through key clinical and regulatory inflection points. This sustained liquidity supports durable investment in trials, partnerships, and enrollment through mid‑2028 without immediate dilution.
Platform DifferentiationProprietary SpiNA chemistry and a bifunctional RNA approach underpin a structural competitive advantage versus standard sRNA or siRNA modalities. Persistent platform differentiation can enable durable clinical differentiation, easier partner attraction, and long‑term IP leverage across multiple genetic indications.
Clinical And Regulatory MomentumCompleted dosing across key WVE‑006 cohorts and an FDA meeting about accelerated approval represent structural de‑risking steps. Regulatory engagement and cohort completion improve the likelihood of clear approval pathways and future milestone payments, strengthening the company's long‑term commercialization prospects.
Bears Say
High Cash Burn & Persistent LossesSustained negative operating and free cash flow indicates the business consumes substantial cash to fund R&D and operations. Over months, persistent burn elevates reliance on external financing or milestone receipts, increasing dilution risk and constraining strategic flexibility if expected funding does not materialize.
Declining Collaboration Revenue & Partner DependenceA sharp drop in collaboration income highlights dependence on sporadic partner payments; recurring operating funding is unstable. This structural reliance means program timelines and liquidity can hinge on partner milestones and negotiations, complicating multi‑year planning and increasing execution risk.
Regulatory, Safety And Competitive UncertaintySafety signals and irreversible editing risks create durable regulatory and payer hurdles for RNA editing and PNPLA3 approaches. Such structural uncertainty can slow approvals, increase required evidence, raise development costs, and push Wave toward partnerships or conservative commercialization strategies.
Wave Life Sciences News
0VS FAQ
What was Wave Life Sciences’s price range in the past 12 months?
Wave Life Sciences lowest stock price was €4.25 and its highest was €17.80 in the past 12 months.
What is Wave Life Sciences’s market cap?
Wave Life Sciences’s market cap is €887.41M.
When is Wave Life Sciences’s upcoming earnings report date?
Wave Life Sciences’s upcoming earnings report date is Nov 05, 2026 which is in 70 days.
How were Wave Life Sciences’s earnings last quarter?
Wave Life Sciences released its earnings results on Jul 30, 2026. The company reported -€0.291 earnings per share for the quarter, missing the consensus estimate of -€0.257 by -€0.034.
Is Wave Life Sciences overvalued?
According to Wall Street analysts Wave Life Sciences’s price is currently Undervalued.
Does Wave Life Sciences pay dividends?
Wave Life Sciences does not currently pay dividends.
What is Wave Life Sciences’s EPS estimate?
Wave Life Sciences’s EPS estimate is -0.28.
How many shares outstanding does Wave Life Sciences have?
Wave Life Sciences has 197,048,170 shares outstanding.
What happened to Wave Life Sciences’s price movement after its last earnings report?
Wave Life Sciences reported an EPS of -€0.291 in its last earnings report, missing expectations of -€0.257. Following the earnings report the stock price went down -2.459%.
Which hedge fund is a major shareholder of Wave Life Sciences?
Currently, no hedge funds are holding shares in DE:0VS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Wave Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€15.20 (211.52% Upside)
€15.20 (211.52% Upside)
Blogger Sentiment
Neutral
DE:0VS Sentiment 50%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
121.24%
Trailing 12-Months
Company Description
Wave Life Sciences
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
0VS Earnings Call
Q2 2026
0:00 / 0:00
0VS Stock 12 Month Forecast
Average Price Target
€15.20
▲(211.52% Upside)
Technical Analysis
Precigen
―
Stoke Therapeutics
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Rapport Therapeutics, Inc.
―